PAP
CTNM

Persistent Asset Partners’s Contineum Therapeutics CTNM Stock Holding History

Persistent Asset Partners’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,853
Closed -$158K – 495
2025
Q4 		$158K Buy
+13,853
New +$158K 0.07% 240

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Persistent Asset Partners's CTNM Position: Q1 2026 in Review

Persistent Asset Partners sold out of Contineum Therapeutics (CTNM) in Q1 2026, closing a stake of 13,853 shares — an estimated $158K sold.

Persistent Asset Partners first reported a position in CTNM in Q4 2025 and held it in 1 quarter. The position peaked at $158K in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Persistent Asset Partners reported no remaining Contineum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 13,853 Contineum Therapeutics shares in Q1 2026, an estimated $158K.
  • Persistent Asset Partners first reported a position in Contineum Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Contineum Therapeutics position peaked at $158K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.